<DOC>
	<DOCNO>NCT00940069</DOCNO>
	<brief_summary>The investigator perform multicenter , open trial use TS gene polymorphism predict advance lung adenocarcinoma effect pemetrexed combined cisplatin regiment first-line treatment .</brief_summary>
	<brief_title>TS Gene Polymorphism Predicts Effect Patients With Advanced Lung Cancer</brief_title>
	<detailed_description>1 . Main eligibility criterion histologic cytologic proof advance non-small-cell lung cancer ( NSCLC ) primary treatment , normal organ function , Eastern Cooperative Oncology Group performance status 0 2 . 2 . All Patients deliver pemetrexed 500 mg/m2 cisplatin 75 mg/m2 less 4 cycle , administer intravenously every 3 week . Response assessment perform every 6 week ; toxicity assessment perform every 3 week . 3 . Primary end point time progression ( TTP ) ; secondary end point objective response rate ( ORR ) , overall survival ( OS ) , toxicity . 4 . The study design evaluate TS ( thymidylate synthase ) gene polymorphism predictor advance lung adenocarcinoma effect pemetrexed combined cisplatin regiment first-line treatment . 5 . Polymorphisms thymidylate synthase investigate peripheral WBC（white blood cell）of patient .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>histologic cytologic proof advance lung adenocarcinoma primary treatment normal organ function Eastern Cooperative Oncology Group performance status 0 2 Symptomatic patient brain metastasis Major organ dysfunction severe heart disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>TS</keyword>
	<keyword>polymorphism</keyword>
	<keyword>lung cancer</keyword>
	<keyword>adenocarcinoma</keyword>
	<keyword>pemetrexed</keyword>
</DOC>